ClinConnect ClinConnect Logo
Search / Trial NCT03798860

Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Launched by HANNOVER MEDICAL SCHOOL · Jan 7, 2019

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how specific treatments, including immunoglobulins, plasmapheresis (a procedure that cleans the blood), and rituximab (a medication that targets certain immune cells), can help manage donor-specific antibodies in patients who have received a lung transplant. These antibodies can sometimes cause problems by attacking the transplanted lung, so understanding how to monitor and treat them is important for improving patient outcomes.

If you or a loved one has had a lung transplant and has been found to have donor-specific antibodies, you may be eligible to participate in this study. There are no age or gender restrictions, and all lung transplant patients with these antibodies are welcome to join. As a participant, you can expect to be closely monitored during the study to see how effective these treatments are in managing your antibody levels. This research aims to provide valuable insights that could lead to better care for future lung transplant recipients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • all patients after lung transplantation with detection of donor-specific antibodies
  • Exclusion Criteria:
  • none

About Hannover Medical School

Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.

Locations

Hannover, , Germany

Patients applied

0 patients applied

Trial Officials

Fabio Ius, Dr.

Principal Investigator

Hannover Medical School

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials